Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration

Oncologist

Volumn 17, Issue 5, 2012, Pages 645-652

  Berruti, Alfredo ^a   Cook, Richard ^b   Saad, Fred ^c   Buttigliero, Consuelo ^a   Lipton, Allan ^d   Tampellini, Marco ^a   Lee, Ker Ai ^b   Coleman, Robert E ^e   Smith, Matthew R ^f  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF WATERLOO   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Bone metastasis; Parathyroid hormone; Prostate cancer; Zoledronic acid

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; CALCIUM; CREATININE; HEMOGLOBIN; PARATHYROID HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG DOSE REDUCTION; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; HYPERPARATHYROIDISM, SECONDARY; IMIDAZOLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84861608587     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0448     Document Type: Article

References (25)

1. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
2. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005;12:549-583.
3. Berruti A, Dogliotti L, Tucci M et al. Hyperparathyroidism due to the so-called bone hunger syndrome in prostate cancer patients. J Clin Endocrinol Metab 2002; 87:1910-1911; author reply 1911.
4. Murray RM, Grill V, Crinis N et al. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001;86:4133-4138.
5. Tucci M, Mosca A, Lamanna G et al. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 2009;12:94-99.
6. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005;62:265-281.
7. Takahashi S, Hakuta M, Aiba K et al. Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr Relat Cancer 2003;10:403-407.
8. Pollock JH, Blaha MJ, Lavish SA et al. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res 1996;11:754-759.
9. Salgado R, Junius S, Benoy I et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642-646.
10. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res 2007;22:1-6.
11. McCarty MF. Parathyroid hormone may be a cancer promoter-an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med Hypotheses 2000;54:475-482.
12. Murray TM, Rao LG, Divieti P et al. Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005;26:78-113.
13. Gensure RC, Gardella TJ, Jppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005; 328:666-678.
14. Hastings RH, Burton DW, Quintana RA et al. Parathyroid hormone-related protein regulates the growth of orthotopic human lung tumors in athymic mice. Cancer 2001;92:1402-1410.
15. Birch MA, Carron JA, Scott M et al. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer 1995;72:90-95.
16. Iwamura M, Abrahamsson PA, Foss KA et al. Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675-679.
17. Carron JA, Fraser WD, Gallagher JA. PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br J Cancer 1997;76:1095-1098.
18. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1:45-52.
19. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
20. Cook RJ, Lawless JF. The Statistical Analysis of Recurrent Events. New York: Springer, 2007.
21. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1989.
22. Themeau TA, Grambsch PM. Extending the Cox Model. New York: Springer, 2000.
23. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
24. Tretli S, Hermes E, Berg JP et al. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009;100:450-454.
25. Santini D, Virzi V, Fratto ME et al. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 2010;10:46-54.